Clinical Trials on Bevacizimab

Total 29 results

Chulalongkorn University

Completed

Topical Bevacizumab for Preventing Recurrent Pterygium

Pterygium | Bevacizumab | VEGF | Anti-VEGF

Thailand
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Not yet recruiting

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Liver Neoplasms | Hepatocellular Carcinoma | Bevacizumab | Toripalimab | Oxaliplatin
Fudan University

Completed

Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

The Patients With CRLM Who Benefit More From Bevacizumab

China
Shanghai Minimally Invasive Surgery Center

Recruiting

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Rectal Cancer | Bevacizumab | Radiotherapy | Neoadjuvant Treatment

China
University Hospital, Tours

Completed

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF) (SAVE)

Cancer | Patient Starting Bevacizumab

France
Centro Nacional de Investigaciones Oncologicas...
Fundacion CRIS de Investigación para Vencer el Cáncer

Completed

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Metastatic Breast Cancer | Bevacizumab-alone Maintenance Treatment Progression

Spain
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Roche Pharma AG

Unknown

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

Breast Cancer | Bevacizumab | Neoadjuvant Chemotherapy | Molecular Targeted Therapy

China
Centre Georges Francois Leclerc

Completed

Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma (BEVACAPI)

Glioblastoma | Metastatic Colorectal Cancer | Bevacizumab | Capillaroscopy

France
Wang Jiayu
Chinese Academy of Medical Sciences

Not yet recruiting

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Breast Neoplasms | Neoplasm Metastasis | Bevacizumab | Drug Therapy

China
Seoul National University Hospital

Recruiting

Ate-Bev Early Response Prediction Model in Advanced HCC

Hepatocellular Carcinoma | Atezolizumab-bevacizumab | Response Evaluation

Korea, Republic of
Ho Sung Kim

Completed

Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

Magnetic Resonance Imaging | Adult Glioblastoma | Bevacizimab

Korea, Republic of
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Completed

Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma

Colon Cancer Treated With Bevacizumab After Colon Surgery

France
Cancer Institute and Hospital, Chinese Academy...

Recruiting

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Bevacizumab | Capecitabine | Metastatic Colorectal Cancer (mCRC) | Oxaliplatin | Tislelizumab | First-Line | MSS/pMMR | RAS-mutated

China
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Sun Yat-sen University

Recruiting

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

Chemotherapy | Advanced Hepatocellular Carcinoma | Bevacizumab | Atezolizumab

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

The Effects of Preoperative Bevacizumab on Perioperative Complications

Colorectal Cancer | Lung Cancer | Bevacizumab | Operation Wound; Infection

China
University Hospital, Caen

Completed

Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen) (ABCHCaen)

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

France
Tianjin Medical University Cancer Institute and...

Recruiting

Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer | Bevacizumab | Tyrosine Kinase Inhibitor

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular Carcinoma | Pulmonary Metastases | Bevacizumab | Liver Cancer Stage IV | Cryoablation | Cadonilimab

China
Iran University of Medical Sciences

Completed

Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment

Diabetic Retinopathy | Pars Plana Vitrectomy | Intravitreal Bevacizumab Injection | Tractional Retinal Detachment

Iran, Islamic Republic of
Peng Zhang

Recruiting

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Bevacizumab | Antineoplastic Agents | Carboplatin | EGFR | Tyrosine Kinase Inhibitor | Locally Advanced Non-Small Cell Lung Cancer | Pemetrexed

China
Far Eastern Memorial Hospital

Completed

Intraperitoneal Chemotherapy Versus Triweekly Chemotherapy

Intraperitoneal Chemotherapy, Bevacizumab, Ovarian Cancer

Taiwan
Sun Yat-sen University

Unknown

Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer

Bevacizumab | Brain Metastases | Non Squamous Non-small Cell Lung Cancer

China
Lei Li

Recruiting

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer | Bevacizumab | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Albumin-bound Paclitaxel

China
Xiaoxiang Chen

Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Adnexal Diseases | Gonadal Disorders | Endocrine Gland Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms and other conditions

China
Sun Yat-sen University

Completed

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases (SUPER BRAIN)

Bevacizumab | Brain Metastases | Immunotherapy | Non-small Cell Lung Cancer Stage II

China
Sun Yat-sen University

Unknown

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Bevacizumab | Brain Metastases | Sintilimab

China
Groupe Hospitalier Pitie-Salpetriere
Institut Curie; Dr Floriane Jochum, Principal Investigator

Active, not recruiting

Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension (IATRO)

Hypertension | Ovarian Cancer | Antiangiogenic-Associated Hypertension | Adjuvant Bevacizumab

France

Clinical Trials on Bevacizimab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations